

Background



- London Cancer Alliance
 - Collaborative partnership of 16 acute providers in south and west London
 - 5.4 million resident population
 - Developed comparative metrics at pathway, provider and LCA wide – quarterly updates
 - Widely shared through cloud based system
 - Bespoke investigations
 - Key focus on cancer data quality; initially staging data, now broadened out
 - Haematology – specific focus on 14/15 on data improvement – volumes and definitions

Haematology pathway group metrics

Last updated September 2014 [Log of updates](#)

1. Cancer Waiting Times

- [1.1. 2 week wait GP urgent referral to 1st seen](#)
- [1.2. 31 day decision to treat to 1st treatment](#)
- [1.3. 31 day subsequent surgery](#)
- [1.4. 31 day subsequent drugs](#)
- [1.5. 31 day subsequent radiotherapy](#)
- [1.6. 62 day GP urgent referral to 1st treatment](#)
- [1.7 62 day consultant upgrade to 1st treatment](#)
- [1.7 62 day GP urgent referral to 1st treatment median waits](#)
- [1.8 62 day GP urgent referral to 1st treatment – distribution of week of treatment](#)
- [1.9 62 day GP urgent head and neck referral to 1st treatment for haematology cancer](#)
- [1.10 62 day GP urgent referral to 1st treatment performance by referral type](#)

2. Data collection

- 2.1 Data quality in MDT feed to NCRS
 - [2.1.1 – Staging](#)
 - [2.1.2 - Basis of diagnosis](#)
 - [2.1.3 - Performance Status](#)
 - [2.1.4 – CNS indicator](#)
- 2.2 – SACT data quality
 - [2.2.1 Leukaemia](#)
 - [2.2.2 Lymphoma](#)
 - [2.2.3 Myeloma](#)

3. Patient experience

- [3.1 NCPES Q12 – Patient felt they were told sensitivity that they had cancer](#)
- [3.2 NCPES Q14 – Patient given written information about type of cancer they had](#)
- [3.3 NCPES Q21 – Patient given name of the CNS in charge](#)
- [3.4 NCPES Q22– Patient finds it easy to contact their CNS](#)
- [3.5 NCPES Q23 – CNS definitely listened carefully the last time spoken to](#)
- [3.6 NCPES Q44 - Always/nearly always enough nurses on duty](#)
- [3.7 NCPES Q47 – All staff asked patient what name they preferred to be called by](#)
- [3.8 NCPES –Q53 – Given clear written information about what should/should not do post discharge](#)
- [3.9 NCPES Q67 - Patient given right amount of information about condition and treatment](#)
- [3.10 NCPES Q68 – Patient offered written assessment and care plan](#)
- [3.11 – NCPES Q70 – Patient’s rating of care ‘excellent’/‘very good’](#)

4. Prevention/Early diagnosis

- 4.1 – Routes to diagnosis
 - [4.1.1 Hodgkin's Lymphoma](#)
 - [4.1.2 Leukaemia:- AML](#)
 - [4.1.3 Leukaemia:- CLL](#)
 - [4.1.4 Leukaemia:- All others](#)
 - [4.1.5 Multiple Myeloma](#)
 - [4.1.6 Non-Hodgkin's Lymphoma](#)

5. Diagnosis

- [5.1 – Proportion of patients discussed at MDT](#)

6. Treatment

- 6.1 – Holistic Needs Assessment
 - [6.1.1- At diagnosis](#)
 - [6.1.2 – End of treatment](#)
- 6.2 – Access to AHP
 - [6.2.1 – Physiotherapist](#)
 - [6.2.2 – Occupational therapist](#)
 - [6.2.3 – Dietician](#)
 - [6.2.4 - Speech and Language therapist](#)
 - [6.2.5 – Lymphedema specialist.](#)
- 6.3 – SACT top 10 regimens
 - [6.3.1 – Leukaemia](#)
 - [6.3.2 – Lymphoma](#)
 - [6.3.3 – Myeloma](#)
- 6.4 – SACT 30,60 and 90 day mortality
 - 6.4.1 Leukaemia- Overall
 - 6.4.2 – Lymphoma - Overall
 - 6.4.3 – Myeloma- Overall
 - 6.4.4 Leukaemia- by regimen
 - 6.4.5 Lymphoma - by regimen
 - 6.4.6 Myeloma - by regimen

7. Incidence/mortality/survival

- 7.1 – Incidence rates
 - [7.1.1 Hodgkin's Lymphoma \(C81\)](#)
 - [7.1.2 Non-Hodgkin's Lymphoma \(C82-85\)](#)
 - [7.1.3 Multiple Myeloma \(C90\)](#)
 - [7.1.4 Leukaemia \(C91-95\)](#)
- 7.2 - Mortality rates
 - [7.2.1 Hodgkin's Lymphoma](#)
 - [7.2.2 Non-Hodgkin's Lymphoma](#)
 - [7.2.3 Multiple Myeloma](#)
 - [7.2.4 Leukaemia](#)
- 7.3.1- Survival rates
 - [All Haematology Cancers](#)
 - [Hodgkin's Lymphoma](#)
 - [Non-Hodgkin's Lymphoma](#)
 - [Multiple Myeloma](#)
 - [Leukaemia](#)
- 7.3.2.1 year survival by Cancer Network
 - [All Haematology Cancers](#)
- 7.3.3 1 year survival by age bracket
 - [All Haematology Cancers](#)
- [7.4 – Number of cases](#)
- [7.5 - Number of deaths](#)
- 7.6 – Prevalence
 - [7.6.1 Non-Hodgkin's Lymphoma – Male](#)
 - [7.6.2 Non-Hodgkin's Lymphoma - Female](#)

8. Cancer Research

- 8.1 NCRN clinical trials data

1.6. 62 day urgent GP referral to 1st treatment

	Q1 2014/15				Q4 2013/14			
	Number	Breaches	Value	Change from Q4 2013/14	Number	Breaches	Value	
Trust/site 7	11	0	100.0%	11.5%	13	1.5	88.5%	
Trust/site 2	8	0	100.0%	25.0%	2	0.5	75.0%	
Trust/site 19	8	0	100.0%	28.6%	7	2	71.4%	
Trust/site 6	7	0	100.0%	54.5%	5.5	3	45.5%	
Trust/site 8	6.5	0	100.0%	7.7%	6.5	0.5	92.3%	
Trust/site 17	5.5	0	100.0%	0.0%	3	0	100.0%	
Trust/site 3	3	0	100.0%	6.3%	8	0.5	93.8%	
Trust/site 1	2.5	0	100.0%	0.0%	3	0	100.0%	
Trust/site 18	6	0.5	91.7%	-8.3%	3.5	0	100.0%	
Trust/site 4	15	1.5	90.0%	-0.9%	11	1	90.9%	
Trust/site 13	16.5	2	87.9%	8.9%	19	4	78.9%	
Trust/site 9	6.5	1	84.6%	-7.1%	6	0.5	91.7%	
Trust/site 12	9.5	1.5	84.2%	-15.8%	8	0	100.0%	
Trust/site 16	11	2	81.8%	-8.5%	15.5	1.5	90.3%	
Trust/site 5	4.5	1	77.8%	-22.2%	8	0	100.0%	
Trust/site 11	7	2	71.4%	26.0%	5.5	3	45.5%	
Trust/site 10	3	1.5	50.0%	-37.5%	8	1	87.5%	
LCA overall	130.5	13	90.0%	4.7%	133	19.5	85.3%	
England Overall			81.5%	-0.8%			82.3%	


* South London Healthcare dissolved

As of the 1st October 2013, with the 3 sites activity moving as follows

- Princess Royal University Hospital joined Kings College Hospital NHS Foundation Trust
- Queen Elizabeth Woolwich, joined Lewisham Hospital to form Lewisham and Greenwich NHS Trust
- Queen Marys Sidcup is now managed by Darrent Valley Hospital (outside the LCA)

The LCA has taken to decision to report performance for the sites of King's College Hospital NHS Foundation Trust and Lewisham and Greenwich NHS Foundation Trust separately given this reorganisation.

Operational standard – 85.0%
(Based on national target)



Source:- Open Exeter


Collated by Stephen Scott stephenscott@nhs.net

In strictest confidence – For NHS internal use only

1.8. 62 day urgent GP referral to 1st treatment distribution of treatment week

Haematology cancers 2012/13

Distribution of when Haematology patients receive their 1st treatment after a 2 week wait referral, to a LCA provider and treated within 2012/13



Source:- Open Exeter extract for 2012/13 – Patients receiving 1st treatment between 1st April 2012 and 31st March 2013.

Extract has been de-duplicated

Total patients on 62 day pathway in 2012/13 - 371.

Total patients on 62 day pathway in 2013/14 – 485 (31% increase)

Collated by Stephen Scott stephenscott@nhs.net

In strictest confidence – For NHS internal use only

1.10. 62 day urgent GP referral to 1st treatment for haematology cancer performance by 2 week wait referral type– 2013/14

2 week wait referral type	Number of patients	Number of breaches	% in target	% of total haematology patients treated on 62 day pathway
Haematology	348	37	89.4%	72.7%
Head and Neck	45	20	55.6%	9.4%
Upper GI	25	7	72.0%	5.2%
Lung	15	1	93.3%	3.1%
Lower GI	13	3	76.9%	2.7%
Breast	8	0	100.0%	1.7%
Skin	7	1	85.7%	1.5%
Urology	6	2	66.7%	1.3%
Sarcoma	6	0	100.0%	1.3%
Gynaecology	4	1	75.0%	0.8%
Other	2	0	100.0%	0.4%
Total (non-haematology)	131	35	73.3%	27.3%
Total	479	72	85.0%	

Operational standard – 85.0%
(Based on national target)


Source:- Open Exeter

Patients with a 1st treatment for haematology cancer (C81-96) who were referred via an urgent 2 week wait referral from GP/GDP, by 2 week wait referral type – treated at a LCA provider

2.1.1 Cancer Registry MDT feed data quality - % of cases fully staged

Quarter 4 2013/14 (January – March 2014) – Haematology

	Q4 2013/14						
	Number of new cases diagnosed	Number which are stage-able	Number stage=able with full valid stage	Number which are not stage-able	% of stage-able cases fully staged	% stage-able and full stage not provided	% unstage-able
Trust/site 2	25	23	19	2	82.6%	17.4%	8.0%
Trust/site 1	17	14	9	3	64.3%	35.7%	17.6%
Trust site 19	17	14	9	3	64.3%	35.7%	17.6%
Trust/site 10	27	22	14	5	63.6%	36.4%	18.5%
Trust/site 16	26	24	14	2	58.3%	41.7%	7.7%
Trust/site 6	21	17	9	4	52.9%	47.1%	19.0%
Trust/site 18	57	36	18	21	50.0%	50.0%	36.8%
Trust/site 13	46	41	20	5	48.8%	51.2%	10.9%
Trust/site 8	27	18	6	9	33.3%	66.7%	33.3%
Trust/site 7	63	46	15	17	32.6%	67.4%	27.0%
Trust/site 5	37	31	7	6	22.6%	77.4%	16.2%
Trust/site 15	29	21	4	8	19.0%	81.0%	27.6%
Trust/site 17	26	20	0	6	0.0%	100.0%	23.1%
Trust/site 4	19	19	0	0	0.0%	100.0%	0.0%
LCA - overall	446	350	145	96	41.4%	58.6%	21.5%



Source:- COSD portal – data extracted 15th September 2014


Collated by Stephen Scott stephenscott@nhs.net
In strictest confidence – For NHS internal use only

Trust reporting less than 10 suppressed

2.1.3 Cancer Registry MDT feed data quality - % of cases with performance status

Quarter 4 2013/14 (January – March 2014) – Haematology

	Q4 2013/14			
	Number of cases discussed at a MDT	Number discussed at a MDT with a performance status	% cases discussed at a MDT with a performance status	% cases discussed at a MDT without a performance status
Trust/site 17	26	25	96.2%	3.8%
Trust/site 5	16	14	87.5%	12.5%
Trust/site 2	25	21	84.0%	16.0%
Trust/site 18	30	11	36.7%	63.3%
Trust/site 7	35	10	28.6%	71.4%
Trust/site 8	18	4	22.2%	77.8%
Trust/site 13	46	0	0.0%	100.0%
Trust/site 10	24	0	0.0%	100.0%
Trust/site 16	19	0	0.0%	100.0%
Trust/site 19	15	0	0.0%	100.0%
Trust/site 15	12	0	0.0%	100.0%
LCA - overall	288	90	31.3%	68.8%



Collated by Stephen Scott stephenscott@nhs.net
In strictest confidence – For NHS internal use only

Source:- COSD portal – data extracted 15th September 2014
Trust's reporting less than 10 cases excluded

2.2.1 Submissions to Systemic Anti-Cancer Therapy (SACT) dataset – Quarter 4 2013/14 –January –March 2014
(Report ran 27th June 2014) – Leukaemia

	Q4 2013/14 (1st January to 31st March 2014)			
	Number of regimens - Submitted in quarter	Data Completeness Morphology	Data Completeness Treatment Intent	Data Completeness Performance status
Trust/site 18	539	100%	0%	3%
Trust/site 6	42	5%	100%	12%
Trust/site 16	42	0%	100%	52%
Trust/site 5	15	0%	0%	0%
Trust/site 8	13	0%	8%	0%
Trust/site 11	10	0%	0%	0%
Trust/site 3	9	0%	100%	100%
Trust/site 13	7	0%	0%	0%
Trust/site 17	6	0%	0%	0%
Trust/site 10	6	67%	100%	100%
Trust/site 19	4	0%	100%	100%
Trust/site 3	3	100%	100%	100%
Trust/site 7	0			
Trust/site 4	0			
Trust/site 1	0			
LCA overall	696	79%	16%	9%
England Overall		41%	69%	28%

Source:- Oxford Cancer Registry report
SACT portal

Key measure of data completeness

Green >70% complete

Yellow 20-70% complete

Red = <20% complete

3.3. % of patients giving positive response to Q21 – Patient given the name of the CNS in charge of their care – NCPES – Haematology

Trust	2012				2011		2010	
	Number of responses	Value	% point change from previous year (from 2011)	% point change in previous 2 years (from 2010)	Number of responses	Value	Number of responses	Value
Trust/site 6	56	100.0%	6.1%	8.1%	73	93.9%	78	91.9%
Trust/site 10	39	97.3%	15.1%	24.6%	46	82.2%	37	72.7%
Trust/site 11	32	93.5%	20.8%	39.3%	30	72.7%	26	54.2%
Trust/site 18	293	92.6%	0.6%	1.7%	223	92.0%	255	90.9%
Trust/site 8	111	91.7%	4.1%	5.5%	91	87.6%	102	86.2%
Trust/site 5	91	90.9%	-6.9%	-0.5%	96	97.8%	62	91.4%
Trust/site 16	92	90.7%	-2.3%	8.9%	94	93.0%	72	81.8%
Trust/site 15	117	88.1%	-1.9%	0.2%	96	90.0%	95	87.9%
Trust/site 17	49	84.8%	-4.1%	0.0%	51	88.9%	37	84.8%
Trust/site 13	63	81.8%	1.2%	-1.8%	64	80.6%	68	83.6%
Trust/site 4	53	80.0%	0.3%	-12.3%	61	79.7%	27	92.3%
Trust/site 7	123	77.9%	-11.6%	16.2%	135	89.5%	127	61.7%
Trust/site 19	40	74.2%	-0.8%	-0.8%	33	75.0%	33	75.0%
Trust/site 3	22	73.7%	-21.5%	-15.6%	25	95.2%	30	89.3%
LCA (Proxy) Overall	1181	88.3%	-0.7%	5.0%	1118	89.1%	1049	83.4%
England Overall		85%	0%	4%		85%		81%


Highlighted in green – Top 20% of trusts England
Highlighted in red – Bottom 20% of trusts England

Source:- National Cancer Experience Survey 2011 & 2010

<http://www.quality-health.co.uk/surveys/2011-2012-cancer-survey-trust-level-reports.html>

Notes:-

- Survey results only published where 20 or more responses received for that tumour type at trust
- Survey response is allocated to trust where patient an inpatient
- Survey covered inpatients during a 3 month period in each of years
- Numbers of patients who responded to any questions on survey is included, however this cannot be translated into number of cases who answered a particular question as patients may not have answered all questions




Compiled by Stephen Scott stephenscott@nhs.net

In strictest confidence – For NHS internal use only

5.1 Proportion of new patients discussed at a MDT meeting Q1 2014/15

Trust	Number of patients treated	Number discussed at MDT	% of patients discussed at MDT	Number not discussed at MDT	Number MDT indicator left blank
Trust/site 2	18	18	100.0%	0	0
Trust/site 11	15	15	100.0%	0	0
Trust/site 17	22	22	100.0%	0	0
Trust/site 11	27	26	96.3%	1	0
Trust/site 13	38	36	94.7%	1	1
Trust/site 9	32	27	84.4%	1	4
Trust/site 5	32	24	75.0%	8	0
Trust/site 1	9	6	66.7%	0	3
Trust/site 18	45	30	66.7%	15	0
Trust/site 3	7	4	57.1%	1	2
Trust/site 12	25	12	48.0%	13	0
Trust/site 19	15	7	46.7%	8	0
Trust/site 8	27	9	33.3%	17	1
Trust/site 7	44	7	15.9%	37	0
Trust/site 6	32	4	12.5%	1	27
Trust/site 4	33	3	9.1%	6	24
Trust/site 15	34	3	8.8%	19	12
LCA total	455	253	55.6%	103	99



Source – Open Exeter – Cancer Waiting Times

Patient receiving their 1st treatment for haematology, using field Multi Disciplinary Team discussion indicator

Collated by Stephen Scott stephenscott@nhs.net

In strictest confidence – For NHS internal use only

6.1.1 HNA assessment results – Q3&Q4 2013/14 returns from trusts (Part 1)

Trust data – HNA offered/completed within 31 days of diagnosis

Trust	Q4					Q3				
	Proxy for number of new patients	Number of HNA offered within 31 days of diagnosis	% patients with HNA offered within 31 days of diagnosis	Numbers of HNA completed within 31 days of diagnosis	% patients with HNA completed within 31 days of diagnosis	Proxy for number of new patients	Number of HNA offered within 31 days of diagnosis	% patients with HNA offered within 31 days of diagnosis	Numbers of HNA completed within 31 days of diagnosis	% patients with HNA completed within 31 days of diagnosis
Trust/site 1	15	7	47%	7	47%	15	9	60%	9	60%
Trust/site 7	47	19	40%	19	40%	48	13	27%	10	21%
Trust/site 5	32	20	63%	12	38%	31	17	55%	11	35%
Trust/site 8	42	24	57%	11	26%	39	0	0%	0	0%
Trust/site 16	24	54	225%	6	25%	39	34	87%	20	51%
Trust/site 6	31	7	23%	7	23%	40	4	10%	4	10%
Trust/site 2	18	0	0%	0	0%	16	0	0%	0	0%
Trust/site 3	15	0	0%	0	0%	6	0	0%	0	0%
Trust/site 4	23	0	0%	0	0%	19	0	0%	0	0%
Trust/site 10	29	16	55%	0	0%	24	14	58%	0	0%
Trust/site 11	33	0	0%	0	0%	34	0	0%	0	0%
Trust/site 13	43	0	0%	0	0%	42	0	0%	0	0%
Trust/site 14	1	0	0%	0	0%					
Trust/site 17	26	0	0%	0	0%	25	0	0%	0	0%
Trust/site 18	32	0	0%	0	0%	45	14	31%	0	0%
Trust/site 19	12	0	0%	0	0%	5	0	0%	0	0%
LCA Total	423	147	35%	62	15%	428	105	25%	54	13%

Trusts who did not submit data in Q4:

- Croydon Healthcare NHS Trust
- East and North Hertfordshire NHS Trust
- West Middlesex University Hospital NHS Trust

Trusts who did not submit data in Q3:

- Croydon Healthcare NHS Trust
- East and North Hertfordshire NHS Trust
- Kings College Hospital Foundation Trust
- West Middlesex University Hospital NHS Trust


The proxy for the number of new cases by trust, is derived by the numbers of 1st treatments reported against the Cancer Waiting Times within the quarter.

Collated by Timothy.bill@nhs.net
In strictest confidence – For NHS internal use only


6.3.1 Leukaemia - Top 10 regimens, submitted to Systemic Anti Cancer Therapy (SACT) dataset – by LCA trust

April 2013 –March 2014 - - Page 2/3

Trust 8




Trust 10




Source:- Oxford
Cancer Registry
report
SACT portal

Extracted 28th
July 2014

Trust 11



Trust 16



Next Steps

- Continued focus on data improvement
- Continued focus on exception reporting via MDT leads
- Development of pathway compliance metrics
 - 30 day mortality post chemotherapy
 - % patients with ALL entered into clinical trials
 - % patients with CNS contact